UC Davis Health’s Investing in the Future of Medicine Fund has made its first investment, backing Delix Therapeutics, a neuroscience company developing treatments for depression and other mental health conditions.

… Future of Medicine (IFM) Fund, backing Delix Therapeutics. Delix, a UC … . Now in clinical trials, Delix’s lead candidate DLX … access to these transformative treatments and improve outcomes for … bring patients FDA-approved, take-home medicines that are …

… next generation of neuropsychiatric drug innovation. On June … — including competitors like Delix and Gilgamesh — are advancing … that next-generation neuropsychiatric treatments will likely hinge … If validated through future trials, it could ultimately help …

… the drug was regulated after use raised significant medical concerns. … of psychedelics as new treatments. However, as David Olson … starting points to make better medicines,” says Olson. “We … chief innovation officer of Delix Therapeutics, a company that …

… and outperformed ketamine in antidepressant potency — all while … psychedelic drug LSD. Drugs like JRT might enable new treatments for … chief innovation officer of Delix Therapeutics, a company … Najafi Research Award in Medicinal Chemistry, the Boone Family …

… antidepressant effects, and improved cognitive flexibility—key challenges in schizophrenia treatment … Neuroscience NewsTo design the drug, dubbed JRT, researchers … and biochemistry and molecular medicine at UC Davis. … innovation officer of Delix Therapeutics, a …

… hallucinogenic drug could help bridge the treatment gap. So companies like Delix Therapeutics … are making new drugs … optimistic that non-hallucinogenic drugs may widen treatment options for patients. …

… chief medical officer of Delix Therapeutics. "The challenge is that these drugs … effects." Koenig believes current antidepressants, while they can improve lives … solve the current issues with antidepressants via the novel neuroplastogen, DLX …

… in a doctor’s office. An oral treatment option gives … in 2025, the pharmaceutical and biotech industries have a significant … precision medicine. Just as CRISPR and GLP-1 drugs revolutionized … 2 trials.” Mark Rus, CEO, Delix Therapeutics Clinical trial changes …

… measurable concentrations of drug in the cerebrospinal fluid … Delix’s neuroplastogens, can be developed into novel treatments … vitro, rapid and enduring antidepressant responses in preclinical models … bring patients FDA-approved, take-home medicines that are …